[go: up one dir, main page]

BR0116212A - 2-azetidinonas açúcar-substituìdas úteis como agentes hipocolesterolêmicos - Google Patents

2-azetidinonas açúcar-substituìdas úteis como agentes hipocolesterolêmicos

Info

Publication number
BR0116212A
BR0116212A BR0116212-8A BR0116212A BR0116212A BR 0116212 A BR0116212 A BR 0116212A BR 0116212 A BR0116212 A BR 0116212A BR 0116212 A BR0116212 A BR 0116212A
Authority
BR
Brazil
Prior art keywords
sugar
substituted
azetidinones useful
hypocholesterolemic agents
agents
Prior art date
Application number
BR0116212-8A
Other languages
English (en)
Inventor
Anima Ghosal
Shmuel Zbaida
Swapan K Chowdhury
Robert M Iannucci
Wenqing Feng
Kevin B Alton
James E Patrick
Harry R Davis
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22973953&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0116212(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR0116212A publication Critical patent/BR0116212A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"2-AZETIDINONAS AçúCAR-SUBSTITUìDAS úTEIS COMO AGENTES HIPOCOLESTEROLêMICOS". Compostos hipocolesterolêmicos de 2-azetitinona açúcar-substituída da fórmula: são divulgados, bem como um método de diminuição de colesterol através de administração dos referidos compostos, composições farmacêuticas contendo os mesmos e a combinação de um agente para diminuição de colesterol de 2-azetidinona açúcar-substituída e um inibidor da biossíntese de colesterol para o tratamento e prevenção de aterosclerose.
BR0116212-8A 2000-12-20 2001-12-17 2-azetidinonas açúcar-substituìdas úteis como agentes hipocolesterolêmicos BR0116212A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25687500P 2000-12-20 2000-12-20
PCT/US2001/049127 WO2002050090A1 (en) 2000-12-20 2001-12-17 Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents

Publications (1)

Publication Number Publication Date
BR0116212A true BR0116212A (pt) 2003-12-30

Family

ID=22973953

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116212-8A BR0116212A (pt) 2000-12-20 2001-12-17 2-azetidinonas açúcar-substituìdas úteis como agentes hipocolesterolêmicos

Country Status (34)

Country Link
US (1) US20020137690A1 (pt)
EP (1) EP1347987B1 (pt)
JP (2) JP4351842B2 (pt)
KR (1) KR100883461B1 (pt)
CN (1) CN100475829C (pt)
AR (1) AR035611A1 (pt)
AT (2) ATE279425T1 (pt)
AU (2) AU3104902A (pt)
BR (1) BR0116212A (pt)
CA (1) CA2432798C (pt)
CY (1) CY1106912T1 (pt)
CZ (1) CZ302193B6 (pt)
DE (2) DE60129863T2 (pt)
DK (2) DK1347987T3 (pt)
EC (1) ECSP034659A (pt)
ES (2) ES2230385T3 (pt)
GE (1) GEP20053548B (pt)
HU (1) HUP0302269A3 (pt)
IL (1) IL155771A0 (pt)
MA (1) MA26975A1 (pt)
MX (1) MXPA03005671A (pt)
MY (1) MY129148A (pt)
NO (2) NO326981B1 (pt)
NZ (1) NZ525722A (pt)
PE (1) PE20020718A1 (pt)
PL (1) PL208242B1 (pt)
PT (2) PT1347987E (pt)
RU (1) RU2297422C2 (pt)
SI (2) SI1593670T1 (pt)
SK (1) SK286703B6 (pt)
TR (1) TR200402758T4 (pt)
TW (1) TWI316942B (pt)
WO (1) WO2002050090A1 (pt)
ZA (1) ZA200303694B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
PL208110B1 (pl) 2001-01-26 2011-03-31 Schering Corp Kompozycja farmaceutyczna
AU2002243557B2 (en) 2001-01-26 2006-01-05 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AU2002258605B2 (en) 2001-03-28 2006-01-12 Merck Sharp & Dohme Corp. Enantioselective synthesis of azetidinone intermediate compounds
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
MXPA05004810A (es) 2002-11-06 2005-07-22 Schering Corp Inhibidores de la absorcion del colesterol para el tratamiento de la desmielinizacion.
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1606287B1 (en) 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1522541A1 (en) * 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
AU2004308332B2 (en) 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
WO2005061452A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
MX2007003732A (es) * 2004-09-29 2007-04-23 Schering Corp Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1.
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
KR20080096851A (ko) * 2006-03-06 2008-11-03 테바 파마슈티컬 인더스트리즈 리미티드 에제티미베 조성물
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
JP5583003B2 (ja) * 2007-04-02 2014-09-03 セラコス・インコーポレイテッド ベンジルグルコシド誘導体およびその用途
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
UA106485C2 (uk) * 2009-02-11 2014-09-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Пестицидні сполуки
CA2754384A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
WO2010113175A2 (en) 2009-04-01 2010-10-07 Matrix Laboratories Ltd Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
KR101102749B1 (ko) * 2009-11-30 2012-01-05 최길용 곱셈 학습기
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
CN105055404B (zh) * 2015-08-19 2017-07-18 四川大学 Hmgcs2抑制剂在制备治疗可卡因成瘾的药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
EP0877750B1 (en) * 1995-10-31 2002-06-19 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AUPQ342599A0 (en) * 1999-10-14 1999-11-04 University Of Melbourne, The Conjugates and uses thereof

Also Published As

Publication number Publication date
PL208242B1 (pl) 2011-04-29
MXPA03005671A (es) 2003-10-06
CN1483039A (zh) 2004-03-17
DE60129863D1 (de) 2007-09-20
NO20083737L (no) 2003-08-19
HUP0302269A3 (en) 2009-08-28
ATE369334T1 (de) 2007-08-15
SI1593670T1 (sl) 2007-12-31
PT1347987E (pt) 2005-01-31
AR035611A1 (es) 2004-06-16
ECSP034659A (es) 2003-07-25
NZ525722A (en) 2004-11-26
GEP20053548B (en) 2005-06-27
CZ20031674A3 (cs) 2003-10-15
ATE279425T1 (de) 2004-10-15
WO2002050090A1 (en) 2002-06-27
HK1056735A1 (en) 2004-02-27
RU2297422C2 (ru) 2007-04-20
CA2432798A1 (en) 2002-06-27
DE60106489T2 (de) 2005-10-13
ES2230385T3 (es) 2005-05-01
CN100475829C (zh) 2009-04-08
IL155771A0 (en) 2003-12-23
EP1347987B1 (en) 2004-10-13
SK286703B6 (sk) 2009-03-05
MY129148A (en) 2007-03-30
SK7702003A3 (en) 2003-10-07
ZA200303694B (en) 2004-08-13
PE20020718A1 (es) 2002-08-09
RU2003122520A (ru) 2005-02-27
CA2432798C (en) 2007-02-27
DK1347987T3 (da) 2005-01-31
HK1084945A1 (en) 2006-08-11
WO2002050090A8 (en) 2004-04-15
TR200402758T4 (tr) 2004-11-22
US20020137690A1 (en) 2002-09-26
KR20030063414A (ko) 2003-07-28
DK1593670T3 (da) 2007-11-05
AU2002231049B2 (en) 2006-07-20
JP2004516299A (ja) 2004-06-03
PL363237A1 (en) 2004-11-15
NO326981B1 (no) 2009-03-30
PT1593670E (pt) 2007-11-08
JP4351842B2 (ja) 2009-10-28
MA26975A1 (fr) 2004-12-20
HUP0302269A2 (hu) 2003-10-28
SI1347987T1 (en) 2005-02-28
TWI316942B (en) 2009-11-11
CZ302193B6 (cs) 2010-12-08
DE60106489D1 (de) 2004-11-18
JP2009132745A (ja) 2009-06-18
KR100883461B1 (ko) 2009-02-16
DE60129863T2 (de) 2008-04-30
AU3104902A (en) 2002-07-01
EP1347987A1 (en) 2003-10-01
CY1106912T1 (el) 2012-09-26
NO20032806D0 (no) 2003-06-19
ES2287826T3 (es) 2007-12-16
NO20032806L (no) 2003-08-19

Similar Documents

Publication Publication Date Title
BR0116212A (pt) 2-azetidinonas açúcar-substituìdas úteis como agentes hipocolesterolêmicos
MX9803447A (es) 2-azetidinonas substituidas con azucares, utiles como agentes hipocolesterolemicos.
DE60315336D1 (de) Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv)
HUP0303876A3 (en) Preparation of pharmaceutical compositions for treatment of type 2 diabetes using piperidine or tiazolidine, inhibitors of dipeptidyl peptidase iv
YU46903A (sh) Derivati difenil-azetidinona,postupak za njihovu proizvodnju lekovi koji sadrže ova jedinjenja i njihova primena
YU47803A (sh) Derivati difenil-azetidinona, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena
WO2001081310A8 (en) 1-aroyl-piperidinyl benzamidines
BRPI0416909A (pt) método de tratamento de aterosclerose
BR0208384A (pt) Sìntese enantiosseletiva de compostos intermediários de azetidinona
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BR9914044A (pt) ésteres tetrahidropirido
MXPA03002779A (es) Derivados de glucopiranosiloxibencilbenceno y composiciones medicinales conteniendo los mismos.
DK0778834T3 (da) Bicykliske, heterocykliske diarylforbindelser som inhibitorer af cyclooxygenase-2
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0210139A (pt) Composições farmacêuticas
DE69825603D1 (de) 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MXPA02010320A (es) Un derivado piridin-1-oxido, y procedimiento para su transformacion en compuestos farmaceuticamente efectivos.
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
NO20072668L (no) Ny kombinasjon
DE69815509D1 (de) Heterozyklische verbindungen die als oxido-squalen-zyklase-inhibitoren anwendung finden
NO20060718L (no) Substituerte tiofoner og deres anvendelse
AU2002339158A1 (en) 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors
BR0014447A (pt) Derivados de piperidina como inibidores da reabsorção
DK1551850T3 (da) 2"-oxo-voruscharin og derivater deraf

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time